Immunosignatures can predict vaccine efficacy

Joseph Barten Legutki, Stephen Johnston

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The development of new vaccines would be greatly facilitated by having effective methods to predict vaccine performance. Such methods could also be helpful in monitoring individual vaccine responses to existing vaccines. We have developed "immunosignaturing" as a simple, comprehensive, chip-based method to display the antibody diversity in an individual on peptide arrays. Here we examined whether this technology could be used to develop correlates for predicting vaccine effectiveness. By using a mouse influenza infection, we show that the immunosignaturing of a natural infection can be used to discriminate a protective from nonprotective vaccine. Further, we demonstrate that an immunosignature can determine which mice receiving the same vaccine will survive. Finally, we show that the peptides comprising the correlate signatures of protection can be used to identify possible epitopes in the influenza virus proteome that are correlates of protection.

Original languageEnglish (US)
Pages (from-to)18614-18619
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number46
DOIs
StatePublished - Nov 12 2013

Fingerprint

Vaccines
Antibody Diversity
Peptides
Proteome
Infection
Orthomyxoviridae
Human Influenza
Epitopes
Technology

Keywords

  • Antibody repertoire
  • Epitope prediction
  • Immune profile
  • Peptide microarray
  • Systems vaccinology

ASJC Scopus subject areas

  • General

Cite this

Immunosignatures can predict vaccine efficacy. / Legutki, Joseph Barten; Johnston, Stephen.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 46, 12.11.2013, p. 18614-18619.

Research output: Contribution to journalArticle

@article{9aaaf976a9144dc899bb68e9f7e7f93b,
title = "Immunosignatures can predict vaccine efficacy",
abstract = "The development of new vaccines would be greatly facilitated by having effective methods to predict vaccine performance. Such methods could also be helpful in monitoring individual vaccine responses to existing vaccines. We have developed {"}immunosignaturing{"} as a simple, comprehensive, chip-based method to display the antibody diversity in an individual on peptide arrays. Here we examined whether this technology could be used to develop correlates for predicting vaccine effectiveness. By using a mouse influenza infection, we show that the immunosignaturing of a natural infection can be used to discriminate a protective from nonprotective vaccine. Further, we demonstrate that an immunosignature can determine which mice receiving the same vaccine will survive. Finally, we show that the peptides comprising the correlate signatures of protection can be used to identify possible epitopes in the influenza virus proteome that are correlates of protection.",
keywords = "Antibody repertoire, Epitope prediction, Immune profile, Peptide microarray, Systems vaccinology",
author = "Legutki, {Joseph Barten} and Stephen Johnston",
year = "2013",
month = "11",
day = "12",
doi = "10.1073/pnas.1309390110",
language = "English (US)",
volume = "110",
pages = "18614--18619",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "46",

}

TY - JOUR

T1 - Immunosignatures can predict vaccine efficacy

AU - Legutki, Joseph Barten

AU - Johnston, Stephen

PY - 2013/11/12

Y1 - 2013/11/12

N2 - The development of new vaccines would be greatly facilitated by having effective methods to predict vaccine performance. Such methods could also be helpful in monitoring individual vaccine responses to existing vaccines. We have developed "immunosignaturing" as a simple, comprehensive, chip-based method to display the antibody diversity in an individual on peptide arrays. Here we examined whether this technology could be used to develop correlates for predicting vaccine effectiveness. By using a mouse influenza infection, we show that the immunosignaturing of a natural infection can be used to discriminate a protective from nonprotective vaccine. Further, we demonstrate that an immunosignature can determine which mice receiving the same vaccine will survive. Finally, we show that the peptides comprising the correlate signatures of protection can be used to identify possible epitopes in the influenza virus proteome that are correlates of protection.

AB - The development of new vaccines would be greatly facilitated by having effective methods to predict vaccine performance. Such methods could also be helpful in monitoring individual vaccine responses to existing vaccines. We have developed "immunosignaturing" as a simple, comprehensive, chip-based method to display the antibody diversity in an individual on peptide arrays. Here we examined whether this technology could be used to develop correlates for predicting vaccine effectiveness. By using a mouse influenza infection, we show that the immunosignaturing of a natural infection can be used to discriminate a protective from nonprotective vaccine. Further, we demonstrate that an immunosignature can determine which mice receiving the same vaccine will survive. Finally, we show that the peptides comprising the correlate signatures of protection can be used to identify possible epitopes in the influenza virus proteome that are correlates of protection.

KW - Antibody repertoire

KW - Epitope prediction

KW - Immune profile

KW - Peptide microarray

KW - Systems vaccinology

UR - http://www.scopus.com/inward/record.url?scp=84887415554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887415554&partnerID=8YFLogxK

U2 - 10.1073/pnas.1309390110

DO - 10.1073/pnas.1309390110

M3 - Article

C2 - 24167296

AN - SCOPUS:84887415554

VL - 110

SP - 18614

EP - 18619

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 46

ER -